Neutralizing antibody (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Neutralizing antibody" in English language version.

refsWebsite

Global rank English rank

55nih.gov

4^th place

33doi.org

2^nd place

6worldcat.org

5^th place

3web.archive.org

1^st place

2semanticscholar.org

11^th place

8^th place

1epfl.ch

4,521^st place

4,877^th place

1about.com

216^th place

186^th place

1biology-online.org

low place

1accessscience.com

low place

1who.int

195^th place

302^nd place

1cdc.gov

218^th place

212^th place

1fda.gov

447^th place

338^th place

1books.google.com

3^rd place

1harvard.edu

18^th place

17^th place

1lanl.gov

3,495^th place

2,913^th place

1nature.com

234^th place

397^th place

about.com (Global: 216^th place; English: 186^th place)

ms.about.com

Stachowiak, Julie (15 August 2008). "Neutralizing Antibodies and Disease-Modifying Therapies for Multiple Sclerosis". About.com. Archived from the original on 4 May 2010. Retrieved 13 June 2009.

accessscience.com (Global: low place; English: low place)

Treffers, Henry P. (2014). "Neutralizing antibody". AccessScience. McGraw-Hill. doi:10.1036/1097-8542.450600.

biology-online.org (Global: low place; English: low place)

"Neutralizing antibody". Biology-Online. 2008. Retrieved 4 July 2009.

books.google.com (Global: 3^rd place; English: 3^rd place)

Kaslow, R. A.; Stanberry, L.R.; Le Duc, J. W., eds. (2014). Viral Infections of Humans: Epidemiology and Control (5th ed.). Springer. p. 56. ISBN 978-1-4899-7448-8. Retrieved 4 April 2020.

cdc.gov (Global: 218^th place; English: 212^th place)

"Our Formulary". Infectious Diseases Laboratories. Centers for Disease Control and Prevention. Archived from the original on 16 December 2016. Retrieved 9 December 2016.

doi.org (Global: 2^nd place; English: 2^nd place)

Mike Recher; Karl S Lang; Lukas Hunziker; Stefan Freigang; Bruno Eschli; Nicola L Harris; Alexander Navarini; Beatrice M Senn; Katja Fink; Marius Lötscher; Lars Hangartner; Raphaël Zellweger; Martin Hersberger; Alexandre Theocharides; Hans Hengartner; Rolf M Zinkernagel (8 August 2004). "Deliberate removal of T cell help improves virus-neutralizing antibody production". Nature Immunology. 5 (9): 934–942. doi:10.1038/ni1102. PMID 15300247. S2CID 1351951.
Klasse, P. J. (9 September 2014). "Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives". Advances in Biology. 2014: 1–24. doi:10.1155/2014/157895. PMC 4835181. PMID 27099867.
Treffers, Henry P. (2014). "Neutralizing antibody". AccessScience. McGraw-Hill. doi:10.1036/1097-8542.450600.
Schmaljohn, AL (July 2013). "Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts". Current HIV Research. 11 (5): 345–53. doi:10.2174/1570162x113116660057. PMID 24191933.
Tirado, SM; Yoon, KJ (2003). "Antibody-dependent enhancement of virus infection and disease". Viral Immunology. 16 (1): 69–86. doi:10.1089/088282403763635465. PMID 12725690.
Dejnirattisai, Wanwisa; Supasa, Piyada; Wongwiwat, Wiyada; Rouvinski, Alexander; Barba-Spaeth, Giovanna; Duangchinda, Thaneeya; Sakuntabhai, Anavaj; Cao-Lormeau, Van-Mai; Malasit, Prida; Rey, Felix A; Mongkolsapaya, Juthathip; Screaton, Gavin R (23 June 2016). "Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus". Nature Immunology. 17 (9): 1102–1108. doi:10.1038/ni.3515. PMC 4994874. PMID 27339099.
Jung, David; Alt, Frederick W (January 2004). "Unraveling V(D)J Recombination". Cell. 116 (2): 299–311. doi:10.1016/S0092-8674(04)00039-X. PMID 14744439.
VanBlargan, Laura A.; Goo, Leslie; Pierson, Theodore C. (2016). "Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity". Microbiology and Molecular Biology Reviews. 80 (4): 989–1010. doi:10.1128/MMBR.00024-15. ISSN 1092-2172. PMC 5116878. PMID 27784796.
Crispin, Max; Ward, Andrew B.; Wilson, Ian A. (20 May 2018). "Structure and Immune Recognition of the HIV Glycan Shield". Annual Review of Biophysics. 47 (1): 499–523. doi:10.1146/annurev-biophys-060414-034156. ISSN 1936-122X. PMC 6163090. PMID 29595997.
Guha, Debjani; Ayyavoo, Velpandi (2013). "Innate Immune Evasion Strategies by Human Immunodeficiency Virus Type 1". ISRN AIDS. 2013 954806. doi:10.1155/2013/954806. ISSN 2090-939X. PMC 3767209. PMID 24052891.
Salazar, Georgina; Zhang, Ningyan; Fu, Tong-Ming; An, Zhiqiang (10 July 2017). "Antibody therapies for the prevention and treatment of viral infections". npj Vaccines. 2 (1): 19. doi:10.1038/s41541-017-0019-3. PMC 5627241. PMID 29263875.
Casadevall, A; Dadachova, E; Pirofski, LA (September 2004). "Passive antibody therapy for infectious diseases". Nature Reviews. Microbiology. 2 (9): 695–703. doi:10.1038/nrmicro974. PMID 15372080.
Kreil, Thomas R. (March 2015). "Treatment of Ebola Virus Infection with Antibodies from Reconvalescent Donors". Emerging Infectious Diseases. 21 (3): 521–523. doi:10.3201/eid2103.141838. PMC 4344290. PMID 25695274.
Schmidt, Rebecca; Beltzig, Lea C.; Sawatsky, Bevan; Dolnik, Olga; Dietzel, Erik; Krähling, Verena; Volz, Asisa; Sutter, Gerd; Becker, Stephan; von Messling, Veronika (5 October 2018). "Generation of therapeutic antisera for emerging viral infections". npj Vaccines. 3 (1): 42. doi:10.1038/s41541-018-0082-4. PMC 6173733. PMID 30323953.
Hung, I. F.; To, K. K.; Lee, C.-K.; Lee, K.-L.; Chan, K.; Yan, W.-W.; Liu, R.; Watt, C.-L.; Chan, W.-M.; Lai, K.-Y.; Koo, C.-K.; Buckley, T.; Chow, F.-L.; Wong, K.-K.; Chan, H.-S.; Ching, C.-K.; Tang, B. S.; Lau, C. C.; Li, I. W.; Liu, S.-H.; Chan, K.-H.; Lin, C.-K.; Yuen, K.-Y. (19 January 2011). "Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection". Clinical Infectious Diseases. 52 (4): 447–456. doi:10.1093/cid/ciq106. PMC 7531589. PMID 21248066.
Shen, Chenguang; Wang, Zhaoqin; Zhao, Fang; Yang, Yang; Li, Jinxiu; Yuan, Jing; Wang, Fuxiang; Li, Delin; Yang, Minghui; Xing, Li; Wei, Jinli; Xiao, Haixia; Yang, Yan; Qu, Jiuxin; Qing, Ling; Chen, Li; Xu, Zhixiang; Peng, Ling; Li, Yanjie; Zheng, Haixia; Chen, Feng; Huang, Kun; Jiang, Yujing; Liu, Dongjing; Zhang, Zheng; Liu, Yingxia; Liu, Lei (27 March 2020). "Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma". JAMA. 323 (16): 1582–1589. doi:10.1001/jama.2020.4783. PMC 7101507. PMID 32219428.
Casadevall, Arturo; Pirofski, Liise-anne (13 March 2020). "The convalescent sera option for containing COVID-19". Journal of Clinical Investigation. 130 (4): 1545–1548. doi:10.1172/JCI138003. PMC 7108922. PMID 32167489.
Bregenholt, S; Jensen, A; Lantto, J; Hyldig, S; Haurum, JS (2006). "Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections". Current Pharmaceutical Design. 12 (16): 2007–15. doi:10.2174/138161206777442173. PMID 16787244.
Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D, et al. (PREVAIL II Writing Group) (13 October 2016). "A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection". New England Journal of Medicine. 375 (15): 1448–1456. doi:10.1056/NEJMoa1604330. PMC 5086427. PMID 27732819.
VanBlargan, Laura A.; Goo, Leslie; Pierson, Theodore C. (26 October 2016). "Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity". Microbiology and Molecular Biology Reviews. 80 (4): 989–1010. doi:10.1128/MMBR.00024-15. PMC 5116878. PMID 27784796.
Kwong, P. D.; Mascola, J. R.; Nabel, G. J. (1 September 2011). "Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1". Cold Spring Harbor Perspectives in Medicine. 1 (1) a007278. doi:10.1101/cshperspect.a007278. PMC 3234457. PMID 22229123.
Burton, Dennis R. (2002). "Antibodies, viruses and vaccines". Nature Reviews Immunology. 2 (9): 706–713. doi:10.1038/nri891. ISSN 1474-1733. PMID 12209139. S2CID 9376285.
Santoro, MM; Perno, CF (2013). "HIV-1 Genetic Variability and Clinical Implications". ISRN Microbiology. 2013 481314. doi:10.1155/2013/481314. PMC 3703378. PMID 23844315.
Kumar, R; Qureshi, H; Deshpande, S; Bhattacharya, J (August 2018). "Broadly neutralizing antibodies in HIV-1 treatment and prevention". Therapeutic Advances in Vaccines and Immunotherapy. 6 (4): 61–68. doi:10.1177/2515135518800689. PMC 6187420. PMID 30345419.
Cohen, J. (2013). "Bound for Glory". Science. 341 (6151): 1168–1171. Bibcode:2013Sci...341.1168C. doi:10.1126/science.341.6151.1168. PMID 24030996.
Simek, MD; Rida, W; Priddy, FH; Pung, P; Carrow, E; Laufer, DS; Lehrman, JK; Boaz, M; Tarragona-Fiol, T; Miiro, G; Birungi, J; Pozniak, A; McPhee, DA; Manigart, O; Karita, E; Inwoley, A; Jaoko, W; Dehovitz, J; Bekker, LG; Pitisuttithum, P; Paris, R; Walker, LM; Poignard, P; Wrin, T; Fast, PE; Burton, DR; Koff, WC (July 2009). "Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm". Journal of Virology. 83 (14): 7337–48. doi:10.1128/JVI.00110-09. PMC 2704778. PMID 19439467.
Haynes, Barton F.; Burton, Dennis R.; Mascola, John R. (30 October 2019). "Multiple roles for HIV broadly neutralizing antibodies". Science Translational Medicine. 11 (516) eaaz2686. doi:10.1126/scitranslmed.aaz2686. PMC 7171597. PMID 31666399.
Corti, D; Cameroni, E; Guarino, B; Kallewaard, NL; Zhu, Q; Lanzavecchia, A (June 2017). "Tackling influenza with broadly neutralizing antibodies". Current Opinion in Virology. 24: 60–69. doi:10.1016/j.coviro.2017.03.002. PMC 7102826. PMID 28527859.
Colbert, MD; Flyak, AI; Ogega, CO; Kinchen, VJ; Massaccesi, G; Hernandez, M; Davidson, E; Doranz, BJ; Cox, AL; Crowe JE, Jr; Bailey, JR (15 July 2019). "Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2". Journal of Virology. 93 (14). doi:10.1128/JVI.02070-18. PMC 6600205. PMID 31068427.
Durham, ND; Agrawal, A; Waltari, E; Croote, D; Zanini, F; Fouch, M; Davidson, E; Smith, O; Carabajal, E; Pak, JE; Doranz, BJ; Robinson, M; Sanz, AM; Albornoz, LL; Rosso, F; Einav, S; Quake, SR; McCutcheon, KM; Goo, L (10 December 2019). "Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics". eLife. 8. doi:10.7554/eLife.52384. PMC 6927745. PMID 31820734.
Goo, L; Debbink, K; Kose, N; Sapparapu, G; Doyle, MP; Wessel, AW; Richner, JM; Burgomaster, KE; Larman, BC; Dowd, KA; Diamond, MS; Crowe JE, Jr; Pierson, TC (January 2019). "A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions". Nature Microbiology. 4 (1): 71–77. doi:10.1038/s41564-018-0283-7. PMC 6435290. PMID 30455471.
Bhiman, Jinal N.; Lynch, Rebecca M. (27 March 2017). "Broadly neutralizing antibodies as treatment: effects on virus and immune system". Current HIV/AIDS Reports. 14 (2): 54–62. doi:10.1007/s11904-017-0352-1. ISSN 1548-3568. PMC 5401706. PMID 28349376.
Kim, Soohyun; Radford, Caelan E.; Xu, Duo; Zhong, Jianing; Do, Jonathan; Pham, Dominic M.; Travisano, Katie A.; Filsinger Interrante, Maria V.; Bruun, Theodora U. J.; Rezek, Valerie; Wilder, Bailey; Palomares, Martina; Seaman, Michael S.; Kitchen, Scott G.; Bloom, Jesse D. (18 May 2025). "A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning". Nature Communications. 16 (1): 4617. doi:10.1038/s41467-025-60035-6. ISSN 2041-1723. PMC 12086220.

epfl.ch (Global: 4,521^st place; English: 4,877^th place)

infoscience.epfl.ch

Mike Recher; Karl S Lang; Lukas Hunziker; Stefan Freigang; Bruno Eschli; Nicola L Harris; Alexander Navarini; Beatrice M Senn; Katja Fink; Marius Lötscher; Lars Hangartner; Raphaël Zellweger; Martin Hersberger; Alexandre Theocharides; Hans Hengartner; Rolf M Zinkernagel (8 August 2004). "Deliberate removal of T cell help improves virus-neutralizing antibody production". Nature Immunology. 5 (9): 934–942. doi:10.1038/ni1102. PMID 15300247. S2CID 1351951.

fda.gov (Global: 447^th place; English: 338^th place)

accessdata.fda.gov

"Label - Palivizumab (Synagis), Medimmune, Incorporated" (PDF). Archived from the original (PDF) on 5 January 2012. Retrieved 4 February 2020.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Cohen, J. (2013). "Bound for Glory". Science. 341 (6151): 1168–1171. Bibcode:2013Sci...341.1168C. doi:10.1126/science.341.6151.1168. PMID 24030996.

lanl.gov (Global: 3,495^th place; English: 2,913^th place)

hiv.lanl.gov

"HIV Databases". Los Alamos National Laboratory.

nature.com (Global: 234^th place; English: 397^th place)

Kim, Soohyun; Radford, Caelan E.; Xu, Duo; Zhong, Jianing; Do, Jonathan; Pham, Dominic M.; Travisano, Katie A.; Filsinger Interrante, Maria V.; Bruun, Theodora U. J.; Rezek, Valerie; Wilder, Bailey; Palomares, Martina; Seaman, Michael S.; Kitchen, Scott G.; Bloom, Jesse D. (18 May 2025). "A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning". Nature Communications. 16 (1): 4617. doi:10.1038/s41467-025-60035-6. ISSN 2041-1723. PMC 12086220.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Mike Recher; Karl S Lang; Lukas Hunziker; Stefan Freigang; Bruno Eschli; Nicola L Harris; Alexander Navarini; Beatrice M Senn; Katja Fink; Marius Lötscher; Lars Hangartner; Raphaël Zellweger; Martin Hersberger; Alexandre Theocharides; Hans Hengartner; Rolf M Zinkernagel (8 August 2004). "Deliberate removal of T cell help improves virus-neutralizing antibody production". Nature Immunology. 5 (9): 934–942. doi:10.1038/ni1102. PMID 15300247. S2CID 1351951.
Klasse, P. J. (9 September 2014). "Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives". Advances in Biology. 2014: 1–24. doi:10.1155/2014/157895. PMC 4835181. PMID 27099867.
Schmaljohn, AL (July 2013). "Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts". Current HIV Research. 11 (5): 345–53. doi:10.2174/1570162x113116660057. PMID 24191933.
Tirado, SM; Yoon, KJ (2003). "Antibody-dependent enhancement of virus infection and disease". Viral Immunology. 16 (1): 69–86. doi:10.1089/088282403763635465. PMID 12725690.
Dejnirattisai, Wanwisa; Supasa, Piyada; Wongwiwat, Wiyada; Rouvinski, Alexander; Barba-Spaeth, Giovanna; Duangchinda, Thaneeya; Sakuntabhai, Anavaj; Cao-Lormeau, Van-Mai; Malasit, Prida; Rey, Felix A; Mongkolsapaya, Juthathip; Screaton, Gavin R (23 June 2016). "Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus". Nature Immunology. 17 (9): 1102–1108. doi:10.1038/ni.3515. PMC 4994874. PMID 27339099.
Jung, David; Alt, Frederick W (January 2004). "Unraveling V(D)J Recombination". Cell. 116 (2): 299–311. doi:10.1016/S0092-8674(04)00039-X. PMID 14744439.
VanBlargan, Laura A.; Goo, Leslie; Pierson, Theodore C. (2016). "Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity". Microbiology and Molecular Biology Reviews. 80 (4): 989–1010. doi:10.1128/MMBR.00024-15. ISSN 1092-2172. PMC 5116878. PMID 27784796.
Crispin, Max; Ward, Andrew B.; Wilson, Ian A. (20 May 2018). "Structure and Immune Recognition of the HIV Glycan Shield". Annual Review of Biophysics. 47 (1): 499–523. doi:10.1146/annurev-biophys-060414-034156. ISSN 1936-122X. PMC 6163090. PMID 29595997.
Guha, Debjani; Ayyavoo, Velpandi (2013). "Innate Immune Evasion Strategies by Human Immunodeficiency Virus Type 1". ISRN AIDS. 2013 954806. doi:10.1155/2013/954806. ISSN 2090-939X. PMC 3767209. PMID 24052891.
Salazar, Georgina; Zhang, Ningyan; Fu, Tong-Ming; An, Zhiqiang (10 July 2017). "Antibody therapies for the prevention and treatment of viral infections". npj Vaccines. 2 (1): 19. doi:10.1038/s41541-017-0019-3. PMC 5627241. PMID 29263875.
Casadevall, A; Dadachova, E; Pirofski, LA (September 2004). "Passive antibody therapy for infectious diseases". Nature Reviews. Microbiology. 2 (9): 695–703. doi:10.1038/nrmicro974. PMID 15372080.
Kreil, Thomas R. (March 2015). "Treatment of Ebola Virus Infection with Antibodies from Reconvalescent Donors". Emerging Infectious Diseases. 21 (3): 521–523. doi:10.3201/eid2103.141838. PMC 4344290. PMID 25695274.
Schmidt, Rebecca; Beltzig, Lea C.; Sawatsky, Bevan; Dolnik, Olga; Dietzel, Erik; Krähling, Verena; Volz, Asisa; Sutter, Gerd; Becker, Stephan; von Messling, Veronika (5 October 2018). "Generation of therapeutic antisera for emerging viral infections". npj Vaccines. 3 (1): 42. doi:10.1038/s41541-018-0082-4. PMC 6173733. PMID 30323953.
Hung, I. F.; To, K. K.; Lee, C.-K.; Lee, K.-L.; Chan, K.; Yan, W.-W.; Liu, R.; Watt, C.-L.; Chan, W.-M.; Lai, K.-Y.; Koo, C.-K.; Buckley, T.; Chow, F.-L.; Wong, K.-K.; Chan, H.-S.; Ching, C.-K.; Tang, B. S.; Lau, C. C.; Li, I. W.; Liu, S.-H.; Chan, K.-H.; Lin, C.-K.; Yuen, K.-Y. (19 January 2011). "Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection". Clinical Infectious Diseases. 52 (4): 447–456. doi:10.1093/cid/ciq106. PMC 7531589. PMID 21248066.
Shen, Chenguang; Wang, Zhaoqin; Zhao, Fang; Yang, Yang; Li, Jinxiu; Yuan, Jing; Wang, Fuxiang; Li, Delin; Yang, Minghui; Xing, Li; Wei, Jinli; Xiao, Haixia; Yang, Yan; Qu, Jiuxin; Qing, Ling; Chen, Li; Xu, Zhixiang; Peng, Ling; Li, Yanjie; Zheng, Haixia; Chen, Feng; Huang, Kun; Jiang, Yujing; Liu, Dongjing; Zhang, Zheng; Liu, Yingxia; Liu, Lei (27 March 2020). "Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma". JAMA. 323 (16): 1582–1589. doi:10.1001/jama.2020.4783. PMC 7101507. PMID 32219428.
Casadevall, Arturo; Pirofski, Liise-anne (13 March 2020). "The convalescent sera option for containing COVID-19". Journal of Clinical Investigation. 130 (4): 1545–1548. doi:10.1172/JCI138003. PMC 7108922. PMID 32167489.
Bregenholt, S; Jensen, A; Lantto, J; Hyldig, S; Haurum, JS (2006). "Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections". Current Pharmaceutical Design. 12 (16): 2007–15. doi:10.2174/138161206777442173. PMID 16787244.
Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D, et al. (PREVAIL II Writing Group) (13 October 2016). "A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection". New England Journal of Medicine. 375 (15): 1448–1456. doi:10.1056/NEJMoa1604330. PMC 5086427. PMID 27732819.
VanBlargan, Laura A.; Goo, Leslie; Pierson, Theodore C. (26 October 2016). "Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity". Microbiology and Molecular Biology Reviews. 80 (4): 989–1010. doi:10.1128/MMBR.00024-15. PMC 5116878. PMID 27784796.
Kwong, P. D.; Mascola, J. R.; Nabel, G. J. (1 September 2011). "Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1". Cold Spring Harbor Perspectives in Medicine. 1 (1) a007278. doi:10.1101/cshperspect.a007278. PMC 3234457. PMID 22229123.
Burton, Dennis R. (2002). "Antibodies, viruses and vaccines". Nature Reviews Immunology. 2 (9): 706–713. doi:10.1038/nri891. ISSN 1474-1733. PMID 12209139. S2CID 9376285.
Santoro, MM; Perno, CF (2013). "HIV-1 Genetic Variability and Clinical Implications". ISRN Microbiology. 2013 481314. doi:10.1155/2013/481314. PMC 3703378. PMID 23844315.
Kumar, R; Qureshi, H; Deshpande, S; Bhattacharya, J (August 2018). "Broadly neutralizing antibodies in HIV-1 treatment and prevention". Therapeutic Advances in Vaccines and Immunotherapy. 6 (4): 61–68. doi:10.1177/2515135518800689. PMC 6187420. PMID 30345419.
Cohen, J. (2013). "Bound for Glory". Science. 341 (6151): 1168–1171. Bibcode:2013Sci...341.1168C. doi:10.1126/science.341.6151.1168. PMID 24030996.
Simek, MD; Rida, W; Priddy, FH; Pung, P; Carrow, E; Laufer, DS; Lehrman, JK; Boaz, M; Tarragona-Fiol, T; Miiro, G; Birungi, J; Pozniak, A; McPhee, DA; Manigart, O; Karita, E; Inwoley, A; Jaoko, W; Dehovitz, J; Bekker, LG; Pitisuttithum, P; Paris, R; Walker, LM; Poignard, P; Wrin, T; Fast, PE; Burton, DR; Koff, WC (July 2009). "Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm". Journal of Virology. 83 (14): 7337–48. doi:10.1128/JVI.00110-09. PMC 2704778. PMID 19439467.
Haynes, Barton F.; Burton, Dennis R.; Mascola, John R. (30 October 2019). "Multiple roles for HIV broadly neutralizing antibodies". Science Translational Medicine. 11 (516) eaaz2686. doi:10.1126/scitranslmed.aaz2686. PMC 7171597. PMID 31666399.
Corti, D; Cameroni, E; Guarino, B; Kallewaard, NL; Zhu, Q; Lanzavecchia, A (June 2017). "Tackling influenza with broadly neutralizing antibodies". Current Opinion in Virology. 24: 60–69. doi:10.1016/j.coviro.2017.03.002. PMC 7102826. PMID 28527859.
Colbert, MD; Flyak, AI; Ogega, CO; Kinchen, VJ; Massaccesi, G; Hernandez, M; Davidson, E; Doranz, BJ; Cox, AL; Crowe JE, Jr; Bailey, JR (15 July 2019). "Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2". Journal of Virology. 93 (14). doi:10.1128/JVI.02070-18. PMC 6600205. PMID 31068427.
Durham, ND; Agrawal, A; Waltari, E; Croote, D; Zanini, F; Fouch, M; Davidson, E; Smith, O; Carabajal, E; Pak, JE; Doranz, BJ; Robinson, M; Sanz, AM; Albornoz, LL; Rosso, F; Einav, S; Quake, SR; McCutcheon, KM; Goo, L (10 December 2019). "Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics". eLife. 8. doi:10.7554/eLife.52384. PMC 6927745. PMID 31820734.
Goo, L; Debbink, K; Kose, N; Sapparapu, G; Doyle, MP; Wessel, AW; Richner, JM; Burgomaster, KE; Larman, BC; Dowd, KA; Diamond, MS; Crowe JE, Jr; Pierson, TC (January 2019). "A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions". Nature Microbiology. 4 (1): 71–77. doi:10.1038/s41564-018-0283-7. PMC 6435290. PMID 30455471.
Bhiman, Jinal N.; Lynch, Rebecca M. (27 March 2017). "Broadly neutralizing antibodies as treatment: effects on virus and immune system". Current HIV/AIDS Reports. 14 (2): 54–62. doi:10.1007/s11904-017-0352-1. ISSN 1548-3568. PMC 5401706. PMID 28349376.

ncbi.nlm.nih.gov

Klasse, P. J. (9 September 2014). "Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives". Advances in Biology. 2014: 1–24. doi:10.1155/2014/157895. PMC 4835181. PMID 27099867.
Dejnirattisai, Wanwisa; Supasa, Piyada; Wongwiwat, Wiyada; Rouvinski, Alexander; Barba-Spaeth, Giovanna; Duangchinda, Thaneeya; Sakuntabhai, Anavaj; Cao-Lormeau, Van-Mai; Malasit, Prida; Rey, Felix A; Mongkolsapaya, Juthathip; Screaton, Gavin R (23 June 2016). "Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus". Nature Immunology. 17 (9): 1102–1108. doi:10.1038/ni.3515. PMC 4994874. PMID 27339099.
VanBlargan, Laura A.; Goo, Leslie; Pierson, Theodore C. (2016). "Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity". Microbiology and Molecular Biology Reviews. 80 (4): 989–1010. doi:10.1128/MMBR.00024-15. ISSN 1092-2172. PMC 5116878. PMID 27784796.
Crispin, Max; Ward, Andrew B.; Wilson, Ian A. (20 May 2018). "Structure and Immune Recognition of the HIV Glycan Shield". Annual Review of Biophysics. 47 (1): 499–523. doi:10.1146/annurev-biophys-060414-034156. ISSN 1936-122X. PMC 6163090. PMID 29595997.
Guha, Debjani; Ayyavoo, Velpandi (2013). "Innate Immune Evasion Strategies by Human Immunodeficiency Virus Type 1". ISRN AIDS. 2013 954806. doi:10.1155/2013/954806. ISSN 2090-939X. PMC 3767209. PMID 24052891.
Salazar, Georgina; Zhang, Ningyan; Fu, Tong-Ming; An, Zhiqiang (10 July 2017). "Antibody therapies for the prevention and treatment of viral infections". npj Vaccines. 2 (1): 19. doi:10.1038/s41541-017-0019-3. PMC 5627241. PMID 29263875.
Kreil, Thomas R. (March 2015). "Treatment of Ebola Virus Infection with Antibodies from Reconvalescent Donors". Emerging Infectious Diseases. 21 (3): 521–523. doi:10.3201/eid2103.141838. PMC 4344290. PMID 25695274.
Schmidt, Rebecca; Beltzig, Lea C.; Sawatsky, Bevan; Dolnik, Olga; Dietzel, Erik; Krähling, Verena; Volz, Asisa; Sutter, Gerd; Becker, Stephan; von Messling, Veronika (5 October 2018). "Generation of therapeutic antisera for emerging viral infections". npj Vaccines. 3 (1): 42. doi:10.1038/s41541-018-0082-4. PMC 6173733. PMID 30323953.
Hung, I. F.; To, K. K.; Lee, C.-K.; Lee, K.-L.; Chan, K.; Yan, W.-W.; Liu, R.; Watt, C.-L.; Chan, W.-M.; Lai, K.-Y.; Koo, C.-K.; Buckley, T.; Chow, F.-L.; Wong, K.-K.; Chan, H.-S.; Ching, C.-K.; Tang, B. S.; Lau, C. C.; Li, I. W.; Liu, S.-H.; Chan, K.-H.; Lin, C.-K.; Yuen, K.-Y. (19 January 2011). "Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection". Clinical Infectious Diseases. 52 (4): 447–456. doi:10.1093/cid/ciq106. PMC 7531589. PMID 21248066.
Shen, Chenguang; Wang, Zhaoqin; Zhao, Fang; Yang, Yang; Li, Jinxiu; Yuan, Jing; Wang, Fuxiang; Li, Delin; Yang, Minghui; Xing, Li; Wei, Jinli; Xiao, Haixia; Yang, Yan; Qu, Jiuxin; Qing, Ling; Chen, Li; Xu, Zhixiang; Peng, Ling; Li, Yanjie; Zheng, Haixia; Chen, Feng; Huang, Kun; Jiang, Yujing; Liu, Dongjing; Zhang, Zheng; Liu, Yingxia; Liu, Lei (27 March 2020). "Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma". JAMA. 323 (16): 1582–1589. doi:10.1001/jama.2020.4783. PMC 7101507. PMID 32219428.
Casadevall, Arturo; Pirofski, Liise-anne (13 March 2020). "The convalescent sera option for containing COVID-19". Journal of Clinical Investigation. 130 (4): 1545–1548. doi:10.1172/JCI138003. PMC 7108922. PMID 32167489.
Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D, et al. (PREVAIL II Writing Group) (13 October 2016). "A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection". New England Journal of Medicine. 375 (15): 1448–1456. doi:10.1056/NEJMoa1604330. PMC 5086427. PMID 27732819.
VanBlargan, Laura A.; Goo, Leslie; Pierson, Theodore C. (26 October 2016). "Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity". Microbiology and Molecular Biology Reviews. 80 (4): 989–1010. doi:10.1128/MMBR.00024-15. PMC 5116878. PMID 27784796.
Kwong, P. D.; Mascola, J. R.; Nabel, G. J. (1 September 2011). "Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1". Cold Spring Harbor Perspectives in Medicine. 1 (1) a007278. doi:10.1101/cshperspect.a007278. PMC 3234457. PMID 22229123.
Santoro, MM; Perno, CF (2013). "HIV-1 Genetic Variability and Clinical Implications". ISRN Microbiology. 2013 481314. doi:10.1155/2013/481314. PMC 3703378. PMID 23844315.
Kumar, R; Qureshi, H; Deshpande, S; Bhattacharya, J (August 2018). "Broadly neutralizing antibodies in HIV-1 treatment and prevention". Therapeutic Advances in Vaccines and Immunotherapy. 6 (4): 61–68. doi:10.1177/2515135518800689. PMC 6187420. PMID 30345419.
Simek, MD; Rida, W; Priddy, FH; Pung, P; Carrow, E; Laufer, DS; Lehrman, JK; Boaz, M; Tarragona-Fiol, T; Miiro, G; Birungi, J; Pozniak, A; McPhee, DA; Manigart, O; Karita, E; Inwoley, A; Jaoko, W; Dehovitz, J; Bekker, LG; Pitisuttithum, P; Paris, R; Walker, LM; Poignard, P; Wrin, T; Fast, PE; Burton, DR; Koff, WC (July 2009). "Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm". Journal of Virology. 83 (14): 7337–48. doi:10.1128/JVI.00110-09. PMC 2704778. PMID 19439467.
Haynes, Barton F.; Burton, Dennis R.; Mascola, John R. (30 October 2019). "Multiple roles for HIV broadly neutralizing antibodies". Science Translational Medicine. 11 (516) eaaz2686. doi:10.1126/scitranslmed.aaz2686. PMC 7171597. PMID 31666399.
Corti, D; Cameroni, E; Guarino, B; Kallewaard, NL; Zhu, Q; Lanzavecchia, A (June 2017). "Tackling influenza with broadly neutralizing antibodies". Current Opinion in Virology. 24: 60–69. doi:10.1016/j.coviro.2017.03.002. PMC 7102826. PMID 28527859.
Colbert, MD; Flyak, AI; Ogega, CO; Kinchen, VJ; Massaccesi, G; Hernandez, M; Davidson, E; Doranz, BJ; Cox, AL; Crowe JE, Jr; Bailey, JR (15 July 2019). "Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2". Journal of Virology. 93 (14). doi:10.1128/JVI.02070-18. PMC 6600205. PMID 31068427.
Durham, ND; Agrawal, A; Waltari, E; Croote, D; Zanini, F; Fouch, M; Davidson, E; Smith, O; Carabajal, E; Pak, JE; Doranz, BJ; Robinson, M; Sanz, AM; Albornoz, LL; Rosso, F; Einav, S; Quake, SR; McCutcheon, KM; Goo, L (10 December 2019). "Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics". eLife. 8. doi:10.7554/eLife.52384. PMC 6927745. PMID 31820734.
Goo, L; Debbink, K; Kose, N; Sapparapu, G; Doyle, MP; Wessel, AW; Richner, JM; Burgomaster, KE; Larman, BC; Dowd, KA; Diamond, MS; Crowe JE, Jr; Pierson, TC (January 2019). "A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions". Nature Microbiology. 4 (1): 71–77. doi:10.1038/s41564-018-0283-7. PMC 6435290. PMID 30455471.
Bhiman, Jinal N.; Lynch, Rebecca M. (27 March 2017). "Broadly neutralizing antibodies as treatment: effects on virus and immune system". Current HIV/AIDS Reports. 14 (2): 54–62. doi:10.1007/s11904-017-0352-1. ISSN 1548-3568. PMC 5401706. PMID 28349376.
Kim, Soohyun; Radford, Caelan E.; Xu, Duo; Zhong, Jianing; Do, Jonathan; Pham, Dominic M.; Travisano, Katie A.; Filsinger Interrante, Maria V.; Bruun, Theodora U. J.; Rezek, Valerie; Wilder, Bailey; Palomares, Martina; Seaman, Michael S.; Kitchen, Scott G.; Bloom, Jesse D. (18 May 2025). "A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning". Nature Communications. 16 (1): 4617. doi:10.1038/s41467-025-60035-6. ISSN 2041-1723. PMC 12086220.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Mike Recher; Karl S Lang; Lukas Hunziker; Stefan Freigang; Bruno Eschli; Nicola L Harris; Alexander Navarini; Beatrice M Senn; Katja Fink; Marius Lötscher; Lars Hangartner; Raphaël Zellweger; Martin Hersberger; Alexandre Theocharides; Hans Hengartner; Rolf M Zinkernagel (8 August 2004). "Deliberate removal of T cell help improves virus-neutralizing antibody production". Nature Immunology. 5 (9): 934–942. doi:10.1038/ni1102. PMID 15300247. S2CID 1351951.
Burton, Dennis R. (2002). "Antibodies, viruses and vaccines". Nature Reviews Immunology. 2 (9): 706–713. doi:10.1038/nri891. ISSN 1474-1733. PMID 12209139. S2CID 9376285.

web.archive.org (Global: 1^st place; English: 1^st place)

Stachowiak, Julie (15 August 2008). "Neutralizing Antibodies and Disease-Modifying Therapies for Multiple Sclerosis". About.com. Archived from the original on 4 May 2010. Retrieved 13 June 2009.
"Our Formulary". Infectious Diseases Laboratories. Centers for Disease Control and Prevention. Archived from the original on 16 December 2016. Retrieved 9 December 2016.
"Label - Palivizumab (Synagis), Medimmune, Incorporated" (PDF). Archived from the original (PDF) on 5 January 2012. Retrieved 4 February 2020.

who.int (Global: 195^th place; English: 302^nd place)

World Health Organization. "WHO | Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease". WHO. Retrieved 5 April 2020.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

VanBlargan, Laura A.; Goo, Leslie; Pierson, Theodore C. (2016). "Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity". Microbiology and Molecular Biology Reviews. 80 (4): 989–1010. doi:10.1128/MMBR.00024-15. ISSN 1092-2172. PMC 5116878. PMID 27784796.
Crispin, Max; Ward, Andrew B.; Wilson, Ian A. (20 May 2018). "Structure and Immune Recognition of the HIV Glycan Shield". Annual Review of Biophysics. 47 (1): 499–523. doi:10.1146/annurev-biophys-060414-034156. ISSN 1936-122X. PMC 6163090. PMID 29595997.
Guha, Debjani; Ayyavoo, Velpandi (2013). "Innate Immune Evasion Strategies by Human Immunodeficiency Virus Type 1". ISRN AIDS. 2013 954806. doi:10.1155/2013/954806. ISSN 2090-939X. PMC 3767209. PMID 24052891.
Burton, Dennis R. (2002). "Antibodies, viruses and vaccines". Nature Reviews Immunology. 2 (9): 706–713. doi:10.1038/nri891. ISSN 1474-1733. PMID 12209139. S2CID 9376285.
Bhiman, Jinal N.; Lynch, Rebecca M. (27 March 2017). "Broadly neutralizing antibodies as treatment: effects on virus and immune system". Current HIV/AIDS Reports. 14 (2): 54–62. doi:10.1007/s11904-017-0352-1. ISSN 1548-3568. PMC 5401706. PMID 28349376.
Kim, Soohyun; Radford, Caelan E.; Xu, Duo; Zhong, Jianing; Do, Jonathan; Pham, Dominic M.; Travisano, Katie A.; Filsinger Interrante, Maria V.; Bruun, Theodora U. J.; Rezek, Valerie; Wilder, Bailey; Palomares, Martina; Seaman, Michael S.; Kitchen, Scott G.; Bloom, Jesse D. (18 May 2025). "A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning". Nature Communications. 16 (1): 4617. doi:10.1038/s41467-025-60035-6. ISSN 2041-1723. PMC 12086220.

Neutralizing antibody (English Wikipedia)

about.com (Global: 216th place; English: 186th place)

ms.about.com

accessscience.com (Global: low place; English: low place)

biology-online.org (Global: low place; English: low place)

books.google.com (Global: 3rd place; English: 3rd place)

cdc.gov (Global: 218th place; English: 212th place)

doi.org (Global: 2nd place; English: 2nd place)

epfl.ch (Global: 4,521st place; English: 4,877th place)